HTA Quarterly Archive

In this issue, we take a closer look at the utilization of “multiple criteria decision analysis” (MCDA) in health technology appraisals, newer therapies for Cystic Fibrosis, and the regulatory pathways and complexity of health technology assessment (HTA) evidentiary hurdles for new diabetes drugs, devices, and combination technologies.

Read issue

We examine wearable technology and big data, valuing CAR-T therapies, and a look at Catalonia and the region's autonomous healthcare market.

Read issue

We examine the world's second largest pharmaceuticals market as Japan shifts from a traditional reimbursement assessment. We look at new therapies for Tardive Dyskinesea. We also review Taiwan's Center for Drug Evaluation on its 10 year anniversary.

Read issue

We take a look at whether value frameworks are the path to implementing value-based pricing, the EMA's move out of the United Kingdom, and look at the health policy trends in Canada from InnomarLive.

Read issue

We examine oncology appraisal differences between NICE and SMC, market access for cell and gene therapies, and managed entry agreements.

Read issue

We examine medical nutrition reimbursement, severe asthma therapies, and brazil's healthcare market.

Read issue

We take a look at patient input into HTA decisions in 4 countries, examining new therapies for Duchenne Muscular Dystrophy, and understanding the Colombian universal healthcare model.

Read issue

We examine the process to appeal unfavorable NICE decisions, provide insights on immunotherapy coverage and reimbursement, and take a deeper look at global value dossiers.

Read issue

We examine indication-specific pricing in Europe and in the US, approved therapies for multiple myeloma, and take a closer look at Portugal's HTA body, SiNATS.

Read issue

We examine rapid access in the US, UK, and France, targeted therapies for psoriasis and psoriatic arthritis, and explore Singapore's highly efficient healthcare system.

Read issue